The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Part of paid clinical trials in Charlestown, Massachusetts.

Sponsor
Sharmin Ghaznavi
Study ID
NCT06247839
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • Psilocybin — DRUG
    COMP360 (Brand name of psilocybin to be used)

Study Details

This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.

Key Dates

Start date
Sep 10, 2024
Status verified
May 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Psilocybin
    25mg Psilocybin

Primary Outcome Measure

Change in Massachusetts General Hospital Rumination Questionnaire (MGH-RQ) [ Time Frame: Baseline, and 3 weeks, 6 weeks, 9 weeks, and 12 weeks after psilocybin administration. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Athinoula A. Martinos Center for Biomedical ImagingCharlestownMassachusetts02129
Sarah Richter
[email protected]

Find similar trials in Charlestown, MA

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
Athinoula A. Martinos Center for Biomedical Imaging· Charlestown, MA

Related Studies